Earnings Call Intelligence Subscribe
Home › Call Sheets › MRNA › Q4'25
Call sheet · Q4'25

Moderna (MRNA)

Q4'25 earnings call · held February 13, 2026 · compared with the Q3'25 call · management-credibility review
7/12
Disclosure score
1 high, 3 medium, 3 low flags
Financial quality
Bottom line
The sleeper story everyone's missing: Moderna just became a government contractor disguised as a biotech. The 'up to 10% growth' is 100% driven by UK/Canada/Australia partnerships-this isn't commercial market share gains, it's taxpayer-funded revenue diversification. The flu RTF isn't just a regulatory setback, it's an existential threat to their 2028 breakeven model that they quietly abandoned without explanation. Most telling quote: 'Current uncertainty in the U.S. FDA regulatory environment creates real challenges'-that's code for 'our US commercial strategy just died.' The binding constraint isn't demand or manufacturing capacity, it's regulatory approval in their home market. My view changes if they can quantify what 2028 breakeven looks like without flu revenue, or if they start winning commercial market share outside of government contracts.

The 30-second version

  • The sleeper story: Flu vaccine RTF masks deeper regulatory capture risk
  • Revenue growth returning but it's all international partnership money
  • They quietly stopped breaking out COVID vs other revenue

What changed this quarter

MetricQ3'25Q4'25Change
Total Revenue$1.0B Q3 (down 45% YoY)$700M Q4 (vs $1.9B full year)Strong Q4 at high end of guidance range
US Revenue$800M Q3$300M Q4 (vs $1.2B full year)Steep sequential decline as season ended
International Revenue$200M Q3$400M Q4 (vs $700M full year)100% sequential acceleration from partnerships
Cost of Sales$207M Q3 (21% of sales)$868M full year41% decrease YoY despite volume decline
R&D Expenses$801M Q3$3.1B full year31% decrease from clinical efficiency gains
Operating Expenses TotalDown 34% YoY Q3Down $2.2B or 30% full yearMassive cost discipline execution
Net Loss$200M Q3$2.8B full year vs $3.6B in 202422% improvement in loss magnitude
Cash and Investments$6.6B Q3$8.1B Q4Added $600M credit facility draw
Free Cash FlowNot broken out Q3Not disclosed Q4Still hiding this metric
mNEXT Spike Market Share55% of COVID volume Q324% total US retail, 34% in 65+ Q4Strong launch performance maintained

Accountability tracked

8 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full MRNA Q4'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.